345 related articles for article (PubMed ID: 8557296)
1. Systemic fungal infections: major problems in cancer patients.
Powles RL; Mehta J
Indian J Cancer; 1994 Sep; 31(3):180-4. PubMed ID: 8557296
[TBL] [Abstract][Full Text] [Related]
2. Fungal infections in cancer patients: an escalating problem.
Samonis G; Bafaloukos D
In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
[TBL] [Abstract][Full Text] [Related]
3. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
[TBL] [Abstract][Full Text] [Related]
4. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
5. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Prentice AG; Glasmacher A; Djulbegovic B
Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
[No Abstract] [Full Text] [Related]
6. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
7. [Systemic fungal infections in immunocompromised patients].
Zupanić-Krmek D; Nemet D
Acta Med Croatica; 2004; 58(4):251-61. PubMed ID: 15700680
[TBL] [Abstract][Full Text] [Related]
8. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.
Chanock SJ; Walsh TJ
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S15-20. PubMed ID: 8971401
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
[TBL] [Abstract][Full Text] [Related]
10. [New aspects in treatment of systemic mycoses].
Presterl E; Graninger W
Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis.
Wakerly L; Craig AM; Malek M; Hoffmeyer U; Lloyd A; Valette F; Phillips R; Zabihollah M
J Hosp Infect; 1996 May; 33(1):35-48. PubMed ID: 8738200
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
Doubek M; Mayer J; Horký D; Doubek J; Rácil Z; Vorlícek J
Vnitr Lek; 2002 Mar; 48(3):248-54. PubMed ID: 11968587
[TBL] [Abstract][Full Text] [Related]
13. [Pocket guide to invasive mycoses in onco-hematologic patients].
Bermúdez A; Carreras E; De la Cámara R; Eraso E; Fortún J; García-Ruiz JC; Guarro J; Jarque I; Marcos de Lucas E; Mayayo E; Pastor FJ; Pemán J; Pontón J; Quindós G; Salavert M; Sanz MA; Zaragoza R
Rev Iberoam Micol; 2009; Suppl():3-199. PubMed ID: 20143497
[No Abstract] [Full Text] [Related]
14. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
15. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices.
Singh N
Clin Infect Dis; 2001 Nov; 33(10):1692-6. PubMed ID: 11641825
[TBL] [Abstract][Full Text] [Related]
16. Changing epidemiology of systemic fungal infections.
Richardson M; Lass-Flörl C
Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
[TBL] [Abstract][Full Text] [Related]
17. [Mycoses and their treatment in malignant hemopathies].
Martino P; Girmenia C
Recenti Prog Med; 1999 Mar; 90(3):160-8. PubMed ID: 10228357
[TBL] [Abstract][Full Text] [Related]
18. Current approaches to the management of fungal infections in cancer patients: Part 1.
Francis P; Walsh TJ
Oncology (Williston Park); 1992 Apr; 6(4):81-92; discussion 97-100. PubMed ID: 1533782
[TBL] [Abstract][Full Text] [Related]
19. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
20. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
